key: cord-0939309-o8qcn0k1 authors: Deek, Sarah A. title: BPC 157 as Potential Treatment for COVID-19 date: 2021-11-09 journal: Med Hypotheses DOI: 10.1016/j.mehy.2021.110736 sha: 49d103a5f68976cf1a550e2dc30b03b4af1e7a8f doc_id: 939309 cord_uid: o8qcn0k1 The emergence of coronavirus disease (COVID-19) in China at the end of 2019 has caused a large global outbreak. COVID-19 is largely seen as a thrombotic and vascular disease targeting endothelial cells (ECs) throughout the body that can provoke the breakdown of central vascular functions. This explains the complications and multi-organ failure seen in COVID-19 patients including acute respiratory distress syndrome, heart failure, liver damage, and neurological damage. Acknowledging the comorbidities and potential organ injuries throughout the course of COVID-19 is therefore crucial in the clinical management of patients. Here we discuss BPC 157, based primarily on animal model data, as a novel agent that can improve the clinical management of COVID-19 via its innate endothelial protective and cytoprotective properties which leads to improved vascular integrity and immune response, reduced proinflammatory profile, and reduced critical levels of the disease. BPC 157 is a peptide that has demonstrated anti-inflammatory, cytoprotective, and endothelium-protecting effects in different organ systems in various species. BPC 157-activated endothelial nitric oxide synthase (eNOS) is associated with nitric oxide (NO) release, tissue repair and angiomodulatory properties as reported in previous studies. As a result, discussion of its use as a potential prophylactic and complementary treatment is critical. All examined treatments, although potentiality effective against COVID-19, need either appropriate drug development or clinical trial to be suitable for clinical use. Here we focused on the stable gastric pentadecapeptide, BPC 157 as a potential treatment for COVID-19 patients. BPC 157 is a peptide that has demonstrated anti-inflammatory, cytoprotective, and endotheliumprotecting effects in different organ systems in various species. BPC 157 has been reviewed as a likely mediator of Robert's stomach cytoprotection/adaptive cytoprotection and organoprotection model Sikiric et al., 1993 Sikiric et al., , 2012 Sikiric et al., , 2018 . BPC 157 is largely known as an antiulcer agent, shown to be effective in inflammatory bowel disease and multiple sclerosis clinical trials in humans with no side effects (PL 10, PLD 116, PLD 14736, Pliva, Croatia) (Hrelec et al., 2009; Spomenko Ilic et al., 2011; Sikiric et al., 2002 Sikiric et al., , 2016 Sikiric et al., , 2017 Sikiric et al., , 2018 . Preclinical safety evaluation of BPC 157 has concluded it can act as a potential drug for treating various wounds . In animal models, BPC 157 is a proven therapy to treat damage in various organ systems such as the gastrointestinal tract, cardiovascular system, central nervous system (CNS). BPC 157 application reduced oxidative stress (Amic et Here we present the research regarding BPC 157 as a protective agent that exerts pleiotropic effects on organs targeted from SARS-CoV-2, particularly the heart, the liver, and the brain. Here we hypothesize BPC 157 to be a promising treatment for COVID-19 patients. Plausibly, BPC 157 may offer improved COVID-19 outcomes by mitigating cytokine derailment and subsequent multi-organ failure based on its anti-inflammatory, cytoprotective, and endothelium-protecting effects (e.g., through BPC 157-eNOS interactions). Theoretically, BPC-157 applications may obstruct viral replication, improve clinical and biochemical parameters, attenuate organ damage from the systemic alterations, provoked from SARS-CoV-2. BPC 157 as an eNOS promoter BPC 157 is predominately shown to interact eNOS, NO system, and counteracted the adverse effect of L-NAME (i.e., hypertension; lack of NO release in vitro) and L-arginine (i.e.,hypotension; NO overrelease in vitro) (Hsieh et al., 2020; Kang et al., 2018; Seiwerth et al., 2014 Seiwerth et al., , 2018 Sikiric et al., 1997 . BPC 157 applications have directly shown to modulate the vasomotor tone of an isolated aorta in a concentration-and NO-dependent manner via the activation of Src-Cav-1-eNOS pathway in rats. At higher concentrations, BPC 157 slightly increased vasorelaxation in the aorta independent from endothelial activation (Hsieh et al., 2020) . Severe cases of COVID-19 patients can lead to the loss of eNOS activity or eNOS uncoupling by adverse regulation of redox switches in eNOS and its up-/downstream signaling molecules. Endothelial integrity and cellular defense requires eNOS function and its ability to generate NO (Daiber et al., 2019; Pober & Sessa, 2007) . Among the pleiotropic cardiovascular actions of eNOS, the stimulation of NO production underlies major mechanisms that exert anti-apoptotic, anti-inflammatory and oxidative/nitrative-suppressive effects. Ultimately, a pivotal vector that supports endothelial integrity and permeability. NO release is the most studied mediator in the modulation of vascular tone via relaxation of smooth muscle cells, has an antithrombotic role due to the attenuation of platelet activation and aggregation, regulates the migration and adhesion of leukocytes on EC, and inhibits vascular smooth muscle cell proliferation. NO deficiency is indicative of injured vessels; ultimately related to hypertension and thrombus formation frequently seen in severe COVID-19 patients. In practice, NO has been shown to be clinically effective in the treatment of congenital heart disease, mitral valvular disease combined with pulmonary hypertension and in orthotopic cardiac transplantation patients. Notably, eNOS function and activity in the endothelium is not the sole mechanism essential for vascular integrity and homeostasis. Nonetheless, this signaling pathway represents an attractive target for pharmacological therapy of COVID-19 and various cardiovascular diseases. In addition to NO's pivotal role in vasculature maintenance, NO has some anti-viral properties in the body. NO reportedly interferes with the interaction between coronavirus viral S-protein and its cognate host receptor, ACE-2 (Åkerström et al., 2009) . NO or its derivatives has shown to cause a reduction in viral RNA production in the early steps of viral replication, including coronaviruses based on various in vitro and in vivo studies . In operated rats subjected to bilateral carotid artery occlusion, BPC 157 remedied both early and delayed neural hippocampal damage, resolved ischemia/reperfusion injuries in rats and consequently theorized as a therapeutic intervention for stroke (Vukojević et al., 2020) . This therapeutic effect of BPC 157 was observed to be carried out by elevated Egr1, Akt1, Kras, Src, Foxo, Srf, Vegfr2, Nos3, and Nos1,and decreased Nos2, NF-κB (Vukojević et al., 2020) . Increased expression of Nos3, Nos1, and decreased expression of Nos2, NF-κB have all been theorized as strategic therapeutic targets in mitigating SARS-CoV-2 effects on the brain (Miners et al., 2020) . NO released by Nos3 and Nos1 scavenges oxygen free radicals, inhibits the expression of adhesion molecules, and regulates platelet aggregation and lymphocyte adhesion in the brain (Jayaraj et al., 2019; Ulrich et al., 2017) . Furthermore, BPC 157 applications decreased NF-κB, Nos2 gene expression and decreased pro-inflammatory gene Cox-2 in intestinal, liver and brain lesions in rats Lojo et al., 2016) . These decreases are implicated with reduced binding of TNF-α release. Modulating NF-κB, Nos2 and inhibiting TNF-α, Cox-2 release have been targets that can derail the inflammatory cytokine buildup seen in COVID-19 patients (Hariharan et al., 2020; Violi et al., 2020) . These functions are important for cerebral microvascular tone regulation, BBB integrity, and procoagulant stimulation (Daneman & Prat, 2015; Song et al., 2020) . Further, BPC 157 has shown to modulate neurotransmitter systems such as dopaminergic (Sikiric et al., 2002) , serotonergic (Tohyama et al., 2004) , GABAergic (Jelovac et al., 1999) , and opioid systems . Reestablishing homeostasis in these neurotransmitter systems allows better resilience for COVID-19 patients. Together these findings suggest BPC 157 applications may relieve the neuroinflammatory and cerebrovascular complications from COVID-19 such as encephalopathies, strokes, peripheral nerve damage, inflammation of the brain. These mechanisms are considered therapeutic targets in the management and treatment of patients with COVID-19. BPC 157 is a clinical infant with a limited number of published clinical trials in humans, and is investigated among a limited number of labs. Many of the cited studies have not considered potential negatives associated with the use of BPC 157, as well as no clear conflicts in literature-based ideas being seen. The reviewed research is limited in terms of microscopic level measures in various investigations. As a result, the scope of BPC 157 efficacy is incomplete. At present, the majority of studies are predominantly limited to mostly animal models and the efficacy of BPC 157 in humans has not been explored extensively. Since there are obvious differences between rodent and human physiology, caution needs to be practiced in extrapolating the efficacy of novel agents to clinical applications in humans. However, it should be underscored BPC 157 is a peptide derived from human gastric juices, and its stability and protective effect of BPC 157 has been widely reported. The emphasis about the relative paucity of the BPC 157 in human clinical data should not be not be discounted (Gwyer et al., 2019; Seiwerth et al., 2018; Sikiric et al., 2018 Sikiric et al., , 2020 . BPC 157 was proved to be efficacious and safe in the available clinical trials in humans for inflammatory bowel disease, mild to moderate ulcerative colitis (PL-10, PLD-116, PL14736, Pliva, Croatia) (Veljaca et al., 2003; Ruenzi & M, 2005) . A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mildto-moderate ulcerative colitis as well as in the experimental rats' studies (Duzel et al., 2017) . It has been established to have a very safe profile (LD1 could be not achieved, no side effects in clinical trials) (Ruenzi & M, 2005; Seiwerth et al., 2018 . This point has been recently reinforced, in preclinical safety evaluation of BPC 157 in both chronic and acute applications . Therefore, some level of safety in human subjects can be assumed. BPC 157 proposes many potential effects to treat a range of conditions, most notably COVID-19. Notably, BPC 157 eNOS protein represents an attractive therapeutic target that has not yet been pharmacologically employed in COVID-19 patients. BPC 157 plays a role in several biological gene expressions and has demonstrated pleiotropic immunomodulatory properties that have proven extensive beneficial effects in animal models, resolving both localized and systemic damage of soft tissues. BPC 157 has persistently exhibited and has anti-arrhythmic and anti-inflammatory effects and has shown to prevent and reverse thrombosis formation, maintain platelet function, alleviate peripheral vascular occlusion disturbances in animal models. All attributing factors to COVID-19 outcomes. BPC 157 applications may counteract inflammatory derailment, and may demonstrate cytoprotective, endothelial protective properties in COVID-19 patients. As a result, BPC 157 poses as a necessary candidate in need of extensive investigation in preventing severe COVID-19. In animal models, BPC 157 has improved liver enzyme profile and disturbances, lung disturbances, cardiovascular disturbances, cerebrovascular disturbances and promoted homeostasis among neurotransmitter systems. All common complications in COVID-19 patients that can lead to morbidity or long-haul COVID-19. Although in vivo studies of animal models revealed a broad range of protective effects of BPC 157, clinical trials in humans are relatively limited and are necessary to appraise the potential efficacy and scope of BPC 157 in clinical settings for COVID-19. Currently there is insufficient data to conclude either for or against the use of BPC 157 for the treatment of COVID-19 in humans. Nevertheless, all the studies to date that have tested BPC 157 have demonstrated substantial positive healing effects for various injury types in various organ systems. Theoretically, in early stages of the infection, BPC 157 may obstruct viral replication, improve blood vessel integrity, and suppress the onset of virus-induced cytokine cascades. In late stages of the disease, it may facilitate recovery of damaged tissues from severe COVID-19. In addition, BPC 157 as a therapeutic intervention may be a tool to further delineate the relationship between cerebrovascular, cardiovascular, liver and lung toxicity seen in COVID-19 infections. Future clinical trials are needed to prove the potential therapeutic use of BPC 157 in COVID-19 patients. No animal experimentation was used in this paper. The animal-related studies compiled for the purposes of this paper were carried out to high ethical standards. Sources of support or funding None. The authors declare that there are no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. What Open-Lung Biopsy Teaches Us about ARDS in COVID-19 Patients: Mechanisms, Pathology, and Therapeutic Implications Activation of toll-like receptor signaling pathways leading to nitric oxide-mediated antiviral responses Nitric oxide and virus infection Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus Home Nitric Oxide Therapy for COVID-19 Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and Larginine Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: A relation with NO-system Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Tropism in the Lungs, Airways, and Vascular Endothelium of Patients With Fatal Coronavirus Disease 2019: An Autopsy Case Series The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases Newly Identified Cluster of Diseases: Rheumatoid Arthritis, Peptic Ulcer, and Tuberculosis S-nitrosylation of viral proteins: molecular bases for antiviral effect of nitric oxide SARS-CoV-2 infection: The role of cytokines in COVID-19 disease Role of endothelial NAD+ deficiency in age-related vascular dysfunction New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease The blood-brain barrier SARS and MERS: Recent insights into emerging coronaviruses Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine Clinical characteristics and mechanism of liver injury in patients with severe acute respiratory syndrome Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights The role of NO in COVID-19 and potential therapeutic strategies Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats Viral infection at the endothelium The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing Coronaviruses and their therapy The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients Role of nitric oxide in the regulation of lymphocyte apoptosis and HIV-1 replication COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide BPC 157, prophylaxis and therapy Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection Effect of COVID-19 on the Organs Neuroinflammation: friend and foe for ischemic stroke Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches COVID-19 and the liver BPC157 as Potential Agent Rescuing from Cancer Cachexia Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot Pathogen interactions with endothelial cells and the induction of innate and adaptive immunity Gastric Acid Secretion in Chronic Obstructive Pulmonary Emphysema Vascular Endothelial Cell Biology: An Update Lymphatic endothelial cells are a replicative niche for Mycobacterium tuberculosis Getting to the site of inflammation: the leukocyte adhesion cascade updated Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: Reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro Cyclophosphamide induced stomach and duodenal lesions as a NO-system disturbance in rats: L-NAME, L-arginine, stable gastric pentadecapeptide BPC 157 Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis The Nitric Oxide Pathway Provides Innate Antiviral Protection in Conjunction with the Type I Interferon Pathway in Fibroblasts COVID-19, thromboembolic risk, and Virchow's triad: Lesson from the past Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase Cognitive impact of COVID-19: looking beyond the short term Endothelial Cell Contributions to COVID-19 Immunity, endothelial injury and complement-induced coagulopathy in COVID-19 Evolving functions of endothelial cells in inflammation The vascular endothelium: The cornerstone of organ dysfunction in severe SARS-CoV-2 infection Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis An antiviral mechanism of nitric oxide: inhibition of a viral protease BPC 157 and blood vessels BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing Chronic obstructive pulmonary disease, inflammation and co-morbidity -A common inflammatory phenotype? Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation Vascular Endothelial Cells and Innate Immunity. Arteriosclerosis, Thrombosis, and Vascular Biology The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157 Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution? Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications Stable gastric pentadecapeptide BPC 157-NO-system relation Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract Oxidative Stress-Mediated Blood-Brain Barrier (BBB) Disruption in Neurological Diseases Lung lesions and anti-ulcer agents beneficial effect: anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rats BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin Therapy of the rat hemorrhagic cystitis induced by cyclophosphamide. Stable gastric pentadecapeptide BPC 157, Larginine, L-NAME Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions Effects of Pentadecapeptide BPC157 on Regional Serotonin Synthesis in the Rat Brain: α-Methyl-L-Tryptophan Autoradiographic Measurements Traumatic brain injury in mice and pentadecapeptide BPC 157 effect Stable gastric pentadecapeptide BPC 157 studied for inflammatory bowel disease (PLD-116, PL14736, Pliva) induces nitric oxide synthesis Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis Endothelial cell infection and endotheliitis in COVID-19 Endothelial Damage in Acute Respiratory Distress Syndrome Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers Nox2 activation in Covid-19 Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157 The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats Covid-19 and the digestive system Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds Role of epithelial nitric oxide in airway viral infection. Free radical biology & medicine Stable gastric pentadecapeptide BPC 157 and bupivacaine The author would like to acknowledge the support from Karim Karouta The author whose name are listed immediately below certify that they have NO affiliation with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-fi nancial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.